Robert W. Baird initiated coverage on Ambrx Biopharma with a new price target
$AMAM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $16.00